Edwards Lifesciences Corp. (EW) announced after the bell Wednesday that an FDA Advisory Panel voted in favor of recommending approval of the Edwards SAPIEN transcatheter heart valve via transfemoral and transapical delivery, for the treatment of high-risk patients with severe, symptomatic aortic stenosis.
Edwards Lifesciences rose sharply in the first 45 minutes of trade Thursday, but was range-bound for the remainder of the session. Shares finished up by 6.34 at $96.88 on strong volume. The stock surged past resistance and set a new high for the year.
For comments and feedback: editorial@rttnews.com